Pfizer Inc is considering buying India's Agila Specialties, the injectable-medicines unit of Indian drug supplier Strides Arcolab Ltd , for a possible price of $2 billion, Bloomberg reported on Monday.
Pfizer Inc is considering buying India's Agila Specialties, the injectable-medicines unit of Indian drug supplier Strides Arcolab Ltd
Pfizer is doing due diligence and a deal could be reached this quarter, Bloomberg reported, citing unnamed sources.
A Pfizer spokeswoman said the company does not comment on market rumours or speculation.
Agila makes cancer treatments and antibiotics, Bloomberg said.
Pfizer shares were up 23 cents at USD 26.75 on the New York Stock Exchange.
Strides Arcolab stock price
On October 13, 2015, Strides Arcolab closed at Rs 1241.00, down Rs 0.85, or 0.07 percent. The 52-week high of the share was Rs 1373.00 and the 52-week low was Rs 626.15.
The company's trailing 12-month (TTM) EPS was at Rs 92.84 per share as per the quarter ended June 2015. The stock's price-to-earnings (P/E) ratio was 13.37. The latest book value of the company is Rs 247.28 per share. At current value, the price-to-book value of the company is 5.02.
Set email alert for
ADS BY GOOGLE
video of the day
India will not be spared if EMs trend lower: Deutsche Bank